Is it Time to Lyse Our Use of “Lytics” in Central Retinal Artery Occlusion?
Keep the current standard of care in mind while awaiting full details from this trial; however, the publication of a randomized trial using tenecteplase warrants close attention for potential guideline changes. If you encounter a patient with suspected CRAO, ensure your local protocol is up-to-date regarding thrombolytic use and consider consulting ophthalmology immediately to interpret these emerging data.
This article presents the results of a randomized trial evaluating tenecteplase for acute central retinal artery occlusion (CRAO). The publication in the Annals of Emergency Medicine points to a significant reassessment of reperfusion therapy, specifically using thrombolytic agents, in this setting. While the specific outcomes are not detailed here, the mere existence of a major randomized controlled trial suggests a potential shift in standard management guidelines for CRAO. It is important that emergency physicians pay attention to these high-level data as they directly impact acute ophthalmologic workup and intervention decisions. The discussion around 'lytics' implies that established protocols may need updating based on this new evidence.